These findings elucidate a novel GBP1-CDK9-STAT3 signaling axis that promotes PD-L1 expression and contributes to immune evasion in osteosarcoma, providing insights into potential therapeutic targets for enhancing immunotherapy efficacy in this malignancy. Here, STAT3 is linked to osteosarcoma.